Our objective was to determine the best measure of heparin anticoagulation in neonatal patients on extracorporeal membrane oxygenation. Activated clotting time (ACT), activated partial thromboplastin time (aPTT), and antifactor Xa levels, along with corresponding heparin infusion rates and heparin bolus volumes, were collected from neonates receiving ECMO at our institution from 2008 to 2013. After natural log transformation of antifactor Xa, ACT, and aPTT, overall correlations between antifactor Xa levels and either ACT or aPTT and correlations between these tests and heparin infusion rates were evaluated using linear mixed models that accounted for both within- and between-patient correlations. Twenty-six neonates with an average weight of 3.4 kg (standard deviation .7) had a total of 27 separate ECMO runs during the study period. Within each patient, ACT (r = .40, p < .0001) and aPTT (r = .48, p < .0001) were both directly correlated with antifactor Xa levels. In contrast, between patients, only aPTT maintained a direct correlation with antifactor Xa (r = .61, p = .07), whereas ACT showed a statistically significant inverse correlation with antifactor Xa (r = -.48, p = .04). Compared with ACT, aPTT is more consistently reflective of the anticoagulation status both within each patient on ECMO and between patients treated with ECMO. Future efforts to develop standardized heparin infusion algorithms for patients on ECMO should consider using aPTT levels to monitor anticoagulation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557514 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Inadequate Anti-Factor Xa Levels With Daily 40-mg Enoxaparin After Cardiac Surgery.
Ann Thorac Surg Short Rep
September 2024
Department of Cardiovascular and Thoracic Surgery, Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York.
Background: Cardiac surgery patients are at increased risk for venous thromboembolism (VTE). Prevention is the most critical strategy to reduce VTE-associated morbidity and death. However, there is a lack of data on the optimal approach to VTE prophylaxis in this population of high-risk patients.
View Article and Find Full Text PDFConcordance and discordance of anticoagulation assays in children supported by ECMO: The truth is out there.
Perfusion
December 2024
Department of Pediatrics, Section of Pediatric Critical Care Medicine, Yale, New Haven, CT, USA.
Introduction: Extracorporeal membrane oxygenation (ECMO) provides critical support to patients in severe cardiac and respiratory failure, but it requires anticoagulation to prevent complications like bleeding and thrombosis. Heparin, the primary anticoagulant utilized, is monitored by activated partial thromboplastin time (aPTT) and anti-Factor Xa (AntiXa) levels. Discordance between the two assays complicates its titration and the impact on patient outcomes is not well-established.
View Article and Find Full Text PDFBalancing safety and efficacy of low-molecular-weight heparins in neonates: a systematic review.
Res Pract Thromb Haemost
October 2024
Department of Pediatrics-Hematology, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
The rising incidence of venous thromboembolism (VTE) in neonates has led to increased use of low-molecular-weight heparins (LMWHs), but optimal dosages remain uncertain. A serious adverse effect of LMWHs is major bleeding. Given the vulnerability of neonates to major bleeding, we aimed to review therapeutic and prophylactic LMWH dosages to achieve target anti-factor Xa ranges of 0.
View Article and Find Full Text PDFPregnant Woman in Outcomes with Prosthetic Heart Valves.
J Cardiovasc Dev Dis
November 2024
Almazov National Medical Research Centre, St. Petersburg 197341, Russia.
Article Synopsis
- This study investigated thrombotic and hemorrhagic complications during pregnancy, delivery, and postpartum in women with prosthetic heart valves (PHV), covering 88 pregnancies from January 2011 to December 2022.
- Of the pregnancies, 79 resulted in live births, with higher miscarriage rates in the mechanical valve prosthesis (MVP) group compared to the biological valve prosthesis (BVP) group, alongside notable thrombotic complications predominantly in the MVP group.
- While effective anti-factor Xa activity control was noted to reduce thrombotic events, the study highlighted a concerning rate of postpartum hemorrhagic complications, suggesting a need for revising anticoagulant therapy protocols.
Chemokine CXCL13 facilitates anti-FVIII inhibitory antibody development in hemophilia A patients and murine models.
Int Immunopharmacol
December 2024
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Medical Technology and Engineering College of Fujian Medical University, Fuzhou, Fujian, China; Key Laboratory of Clinical Laboratory Technology for Precision Medicine (Fujian Medical University), Fujian Province University, Fuzhou, China. Electronic address:
Article Synopsis
- The study investigates the formation of anti-factor VIII (FVIII) inhibitors in hemophilia A patients and the role of the chemokine CXCL13 in this process.
- It was found that CXCL13 levels were significantly elevated in hemophilia A patients with inhibitors compared to those without, suggesting a link between CXCL13 and inhibitor development.
- The research indicates that targeting CXCL13 could be a promising therapeutic strategy for managing FVIII inhibitors in hemophilia A patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!